Skip to main content

Table 2 Symptoms in patients on somatostatin analogue treatment for metastatic disease from small-intestinal neuroendocrine tumour EORTC QLQ-C30 values expressed as mean (standard deviation). A higher score (1–100) on functional scales represents a higher level of function, while a higher score (1–100) on symptom scales represents a higher level of symptoms

From: Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours

 Baseline1-year follow-up
Functional scores
 Global health status72.5 (20.4)75.5 (18.7)
 Physical functioning80.2 (20.6)82.0 (19.1)
 Role functioning77.5 (27.9)78.4 (23.7)
 Emotional functioning83.1 (21.9)85.4 (17.3)
 Cognitive functioning79.0 (19.0)81.4 (17.3)
 Social functioning71.4 (25.5)78.8 (24.6)
 Financial difficulties5.3 (15.1)5.6 (14.7)
Symptom scores
 Fatigue35.3 (23.0)34.4 (22.1)
 Nausea and vomiting5.5 (10.3)4.8 (9.7)
 Pain22.9 (28.2)19.3 (25.9)
 Dyspnoea25.2 (28.9)22.5 (25.6)
 Insomnia30.7 (36.5)25.4 (29.8)
 Appetite loss9.1 (21.9)7.0 (20.6)
 Constipation14.0 (21.9)10.5 (19.0)
 Diarrhoea51.5 (32.7)42.2 (31.7)